Capricor Therapeutics Inc (NASDAQ:CAPR) Receives $34.50 Consensus PT from Brokerages

by · The Cerbat Gem

Capricor Therapeutics Inc (NASDAQ:CAPR – Get Free Report) has earned a consensus recommendation of “Buy” from the six brokerages that are currently covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $34.50.

Several brokerages have commented on CAPR. Maxim Group boosted their target price on Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. Cantor Fitzgerald upped their price objective on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. Piper Sandler began coverage on shares of Capricor Therapeutics in a research report on Monday, October 21st. They set an “overweight” rating and a $35.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $77.00 price target on shares of Capricor Therapeutics in a report on Thursday, November 14th. Finally, Oppenheimer reiterated an “outperform” rating and set a $15.00 price target on shares of Capricor Therapeutics in a research note on Monday, September 23rd.

Get Our Latest Report on CAPR

Capricor Therapeutics Trading Down 2.3 %

Shares of Capricor Therapeutics stock opened at $13.76 on Thursday. Capricor Therapeutics has a 1-year low of $3.52 and a 1-year high of $23.40. The company has a 50 day moving average of $17.23 and a 200-day moving average of $10.70. The company has a market cap of $625.67 million, a PE ratio of -12.98 and a beta of 3.98.

Institutional Investors Weigh In On Capricor Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CAPR. Main Street Financial Solutions LLC raised its stake in shares of Capricor Therapeutics by 37.5% during the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after acquiring an additional 7,500 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Capricor Therapeutics in the 3rd quarter worth approximately $133,000. Rhumbline Advisers purchased a new position in shares of Capricor Therapeutics in the 2nd quarter valued at approximately $147,000. The Manufacturers Life Insurance Company bought a new stake in shares of Capricor Therapeutics during the third quarter valued at approximately $161,000. Finally, Sassicaia Capital Advisers LLC bought a new stake in shares of Capricor Therapeutics during the third quarter valued at approximately $192,000. 21.68% of the stock is currently owned by institutional investors.

About Capricor Therapeutics

(Get Free Report

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

Featured Stories